Collegium Pharmaceutical, Inc.· COLL
🇺🇸 US · SmallSP600NASDAQ
- Price
- $35.73
- Day
- +0.42%
- Mkt Cap
- $1.16B
- 52W Range
- $29.70 – $50.79
- Volume
- 438.6K
- Beta
- 0.73
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Collegium Pharmaceutical (COLL) is transitioning from a pain-management roll-up to a CNS platform, leveraging stable pain cash flows to fuel ADHD franchise growth. The AZSTARYS acquisition, funded with $350M cash and $300M debt, is expected to deliver $60–70M revenue in 2026 and $50M+ annual synergies within 12 months. COLL's 2026 guidance is $865–895M in revenue and $475–500M adjusted EBITDA, with a 55% margin, reflecting only partial-year AZSTARYS contribution and early synergies.
Read full article
STOUGHTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it will report second quarter 2026 financial results before the market opens on Thursday August 6, 2026.
Read full article
Bessemer Group Inc. grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 48.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 98,020 shares of the specialty pharmaceutical company's stock after purchasing an additional 31,800 shares during the quarter. Bessemer
Read full article
BOSTON--(BUSINESS WIRE)--DivcoWest, a DivCore Capital company and national commercial real estate investment firm, today announced that Collegium Pharmaceutical, a leading biopharmaceutical company, has signed a lease for 40,288 square feet on floors 11 and 12 at One Lincoln in Boston's Financial District. The 36‑story, 1.1‑million‑square‑foot Class A office tower completed a transformative renewal in 2025 and now serves as a landmark next-generation workplace for world-class established and gr.
Read full article
STOUGHTON, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced plans to relocate its corporate headquarters to One Lincoln in downtown Boston in the first quarter of 2027.
Read full article